Global Diverticular Disease Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Diverticular Disease Market Size

• The global diverticular disease market size was valued at USD 1.82 billion in 2024 and is expected to reach USD 3.45 billion by 2032, at a CAGR of 8.27% during the forecast period
• The market growth is largely fueled by the rising prevalence of diverticular disease globally, particularly among aging populations and individuals consuming low-fiber diets. Increasing awareness, improved diagnostic capabilities, and advancements in gastrointestinal treatment methods are contributing significantly to market expansion
• Furthermore, the growing demand for minimally invasive surgical techniques, personalized treatment plans, and advanced biologics is establishing diverticular disease management as a priority in the gastrointestinal therapeutic space. These converging factors are accelerating the uptake of diverticular disease solutions, thereby significantly boosting the industry’s growth

Diverticular Disease Market Analysis

• Diverticular disease, encompassing diverticulosis and diverticulitis, is becoming increasingly prevalent, particularly in aging populations and regions with low-fiber diets. Rising healthcare awareness, improved diagnostics, and shifting dietary patterns have made this condition a significant concern in both developed and developing healthcare systems
• The growing demand for minimally invasive treatment options, early-stage diagnosis, and nutritional intervention programs is driving the expansion of the Diverticular Disease market. Increasing adoption of endoscopic and laparoscopic procedures and the development of novel pharmaceuticals are further fueling growth
• North America dominated the diverticular disease market with the largest revenue share of 38.11% in 2024, supported by a high disease burden among the elderly, robust insurance coverage, and advanced healthcare infrastructure. The U.S. is leading regional growth due to strong investment in gastrointestinal research, early diagnosis programs, and growing uptake of novel therapeutics and digital health solutions for gastrointestinal monitoring
• Asia-Pacific is expected to be the fastest-growing region in the diverticular disease market, projected to expand at a CAGR of 9.1% from 2025 to 2032, driven by increasing urbanization, a shift towards Western dietary habits, rising disposable incomes, and growing awareness of gastrointestinal health. Countries such as China, Japan, and India are key contributors to regional growth
• The Diverticulitis segment dominated the diverticular disease market with a market share of 52.4% in 2024, primarily due to its high clinical prevalence and the substantial need for targeted treatment interventions. The segment’s growth is driven by the increasing incidence of complicated diverticulitis cases and the demand for both surgical and non-surgical therapeutic options, including advanced antibiotics and minimally invasive procedures

Report Scope and Diverticular Disease Market Segmentation

Diverticular Disease Market Trends

“Improved Patient Outcomes Through Digital Innovation and Remote Monitoring”

• A significant and accelerating trend in the global diverticular disease market is the increased adoption of digital health technologies, including remote monitoring tools, mobile health applications, and connected care platforms that empower patients and providers to manage the disease more effectively
  • For instance, platforms such as GI Genius by Medtronic leverage AI to enhance the detection of gastrointestinal abnormalities, aiding in early diagnosis and better clinical decision-making. Similarly, digital tools such as MiHealth help patients track symptoms, manage diet, and communicate efficiently with healthcare providers
• Remote monitoring enables real-time tracking of patient symptoms, medication adherence, and treatment response. This data can be used to adjust care plans proactively, reducing complications and unnecessary hospitalizations. Several telehealth solutions now offer dedicated modules for managing gastrointestinal disorders such as diverticular disease
• The integration of digital solutions with electronic health records (EHRs) allows seamless data sharing between patients, general practitioners, and gastroenterologists. This facilitates faster diagnosis, better coordination of care, and enhanced outcomes
• Companies such as Abbott and Medtronic are investing in smart diagnostics and wearable devices designed for gastrointestinal health monitoring. These innovations offer timely alerts for flare-ups or complications, enabling early medical intervention
• The demand for patient-centric, tech-enabled care is rapidly increasing, especially among aging populations in developed markets. As a result, the Diverticular Disease market is seeing a surge in the adoption of tools that provide continuous care, symptom tracking, and real-time communication between patients and clinicians

Diverticular Disease Market Dynamics

Driver

“Growing Need Due to Aging Population and Changing Dietary Habits”

• The increasing global geriatric population, particularly in high-income and emerging economies, coupled with a rise in low-fiber, processed food consumption, is significantly contributing to the rising prevalence of diverticular disease
  • For instance, a 2023 study published in The Lancet Gastroenterology & Hepatology projected that more than 70% of individuals over the age of 80 may develop diverticulosis, highlighting the scale of the issue and the need for targeted interventions. This surge in disease incidence is expected to drive the growth of the Diverticular Disease market throughout the forecast period
• As healthcare systems and consumers become more proactive in managing chronic gastrointestinal disorders, there's a growing focus on early detection, preventive care, and fiber-rich dietary interventions—all contributing to higher demand for diverticular disease solutions
• Furthermore, technological advancements in diagnostic tools such as CT scans, colonoscopy, and capsule endoscopy are making the detection of diverticular complications more accurate and accessible, which enhances the early management and monitoring of patients
• The growing adoption of minimally invasive procedures and pharmaceutical innovation—including targeted antibiotics, anti-inflammatory agents, and dietary supplements—continues to support the uptake of diverticular disease treatments

Restraint/Challenge

“Limited Awareness and High Treatment Costs in Emerging Economies”

• Despite the increasing prevalence, limited awareness of diverticular disease symptoms and treatment options in developing countries poses a major barrier to timely diagnosis and care. Misdiagnosis or underdiagnosis due to overlap with other gastrointestinal conditions often leads to complications, delaying effective intervention
  • For instance, in many low- and middle-income countries, patients may not seek medical attention until acute diverticulitis occurs, which increases healthcare costs and resource burden on hospitals
• In addition, the cost of advanced imaging (such as CT scans), endoscopy, and surgical intervention remains high in several regions, particularly in rural or underserved communities. These costs can be prohibitive for uninsured or underinsured patients, limiting access to effective care
• While some dietary interventions are cost-effective, premium pharmaceutical treatments, biologics, and laparoscopic surgical equipment can still present affordability challenges.
• Overcoming these challenges will require increased public health education campaigns, better insurance coverage, and greater investment in affordable diagnostic and therapeutic technologies tailored for emerging markets

Diverticular Disease Market Scope

The market is segmented into notable categories based on type, treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the diverticular disease market is segmented into diverticulosis, diverticulitis, and diverticular bleeding. Diverticulitis held the largest revenue share of 52.4% in 2024, driven by its higher clinical burden and treatment demand.

Diverticular Bleeding is expected to grow at the fastest CAGR of 20% from 2025 to 2032, due to the increasing geriatric population prone to GI bleeding.

• By Treatment

On the basis of treatment, the diverticular disease market is segmented into medications, surgery, supportive care, penicillin antibiotic, antibiotics, dietary supplements, and IV fluids. Medications dominated the market with a 38.7% share in 2024, owing to widespread use of antibiotics and pain relief drugs.

Surgery is projected to register the highest CAGR of 7.2% from 2025 to 2032, due to rising complications requiring operative care.

• By Diagnosis

On the basis of diagnosis, the diverticular disease market is segmented into Barium X-ray, CT scan, liver function test, blood test, urine test, and ultrasound. CT scan led the diagnosis segment with a 41.5% market share in 2024, due to its superior diagnostic accuracy.

Ultrasound is expected to see a CAGR of 6.5% from 2025 to 2032, particularly in outpatient and pregnancy-related use cases.

• By Symptoms

On the basis of symptoms, the diverticular disease market is segmented into abdominal pain, fever, constipation, bloating, nausea, diarrhea, and others. The abdominal pain segment dominated the largest market revenue share of 36.2% in 2024, attributed to its high prevalence as a primary symptom across various gastrointestinal and metabolic disorders. Abdominal pain is often the first indicator prompting clinical evaluation, contributing to its diagnostic significance and treatment demand.

The bloating and constipation segment is expected to witness the fastest CAGR of 5.9% from 2025 to 2032, driven by changes in dietary habits, sedentary lifestyles, and increasing awareness regarding gut health management.

• By Dosage

On the basis of dosage, the diverticular disease market is segmented into tablet, injection, and others. The tablet segment held the largest market revenue share of 58.3% in 2024, favored for its convenience, non-invasive nature, and ease of administration in outpatient and home settings. Tablets are widely accepted for both acute and chronic treatments, particularly among adult and pediatric populations.

The injection segment is anticipated to grow at the fastest CAGR of 6.3% from 2025 to 2032, driven by its rapid action in emergency settings and its use in hospitals for severe or acute conditions requiring immediate intervention.

• By Route of Administration

On the basis of route of administration, the diverticular disease market is segmented into oral, intravenous, and others. The oral route accounted for the largest market revenue share of 62.7% in 2024, supported by its patient-friendly profile, cost-effectiveness, and common usage in both prescription and OTC formulations.

The intravenous route is projected to register the highest CAGR of 6.7% during the forecast period, owing to its critical role in delivering immediate therapeutic effects in hospital-based treatments and surgical procedures.

• By End-Users

On the basis of end-users, the diverticular disease market is segmented into clinics, hospitals, and others. The hospital segment held the largest revenue share of 49.8% in 2024, driven by the availability of advanced infrastructure, multi-specialty care, and the management of both acute and complex cases. Hospitals are central hubs for inpatient care and surgical procedures, contributing to this dominance.

The clinic segment is expected to grow at a fastest CAGR of 5.8% from 2025 to 2032, supported by the rise in outpatient visits, follow-up care, and increasing preference for localized treatment centers due to lower waiting times and personalized care.

• By Distribution Channel

On the basis of distribution channel, the diverticular disease market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment led the market with a 45.6% share in 2024, as these outlets cater directly to inpatients and emergency departments, providing controlled and specialty medications.

The online pharmacy segment is projected to witness the highest CAGR of 7.4% during the forecast period, driven by growing e-prescription adoption, telehealth expansion, and consumer preference for home delivery, especially post-COVID-19.

Diverticular Disease Market Regional Analysis

• North America dominated the diverticular disease market with the largest revenue share of 38.11% in 2024, driven by an aging population and increasing prevalence of diverticulitis
• In addition, growing awareness about gastrointestinal health
• Advanced healthcare infrastructure, rising preference for minimally invasive procedures, and the presence of leading pharmaceutical companies are further supporting market growth in the region

U.S. Diverticular Disease Market Insight

The U.S. diverticular disease market captured the largest revenue share of 72.6% within North America in 2024, driven by the high incidence of diverticulosis among aging adults, increased utilization of colonoscopy screening, and early intervention strategies supported by both private and public healthcare systems. Strong insurance coverage, availability of advanced diagnostic technologies, and national awareness campaigns around gut health continue to drive U.S. market dominance.

Europe Diverticular Disease Market Insight

The Europe diverticular disease market is projected to grow at a CAGR of 8.6% from 2025 to 2032, supported by a growing elderly population, high fiber-deficient dietary intake, and enhanced reimbursement policies for gastrointestinal diagnostics. Rising investments in public healthcare systems and increasing use of telehealth for early GI symptom assessment are further fueling demand.

U.K. Diverticular Disease Market Insight

The U.K. diverticular disease market is expected to register a CAGR of 8.9% during the forecast period due to increasing health awareness, national screening programs, and the high burden of gastrointestinal diseases among aging adults. A shift towards dietary modifications and growing digital health interventions for chronic disease management are positively impacting the market.

Germany Diverticular Disease Market Insight

The Germany diverticular disease market is anticipated to grow at a CAGR of 8.7% from 2025 to 2032, owing to the country’s well-established diagnostic infrastructure, high healthcare spending, and focus on early intervention practices for digestive disorders. Moreover, Germany’s demand for personalized medicine and hospital-based care is accelerating adoption of both pharmaceutical and surgical interventions.

Asia-Pacific Diverticular Disease Market Insight

The Asia-Pacific diverticular disease market is poised to grow at the fastest CAGR of 9.1% from 2025 to 2032, driven by rapid urbanization, lifestyle changes, and dietary shifts toward low-fiber, processed foods. Rising healthcare awareness, increasing government investments, and improved access to diagnostics in countries such as China, India, and Japan are driving regional growth.

Japan Diverticular Disease Market Insight

The Japan diverticular disease market is gaining momentum due to its super-aging society, rising awareness of colorectal diseases, and increased use of non-invasive imaging diagnostics. The market is further supported by favorable healthcare policies, innovations in therapeutic protocols, and a growing focus on gut health in elderly care.

China Diverticular Disease Market Insight

The China diverticular disease market held the largest revenue share in Asia-Pacific in 2024, fueled by urbanization, dietary westernization, and government initiatives promoting GI health. China's emergence as a hub for pharmaceutical manufacturing and growing adoption of both OTC supplements and prescribed treatments are significantly driving market expansion.

Diverticular Disease Market Share

The diverticular disease industry is primarily led by well-established companies, including:

• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Melinta Therapeutics LLC (U.S.)
• Nabriva Therapeutics plc (Ireland)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Vitaris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Lupin (India)
• AbbVie Inc. (U.S.)

Latest Developments in Global Diverticular Disease Market

• In February 2025, Guts UK and Bowel Research UK published the final report from their Diverticular Disease Priority Setting Partnership (PSP), identifying the top 10 research priorities—including flare‑up management, prevention strategies, microbiome role, and long‑term diet. This report sets the agenda for future clinical studies aimed at improving patient outcomes
• In April 2025, Spanish biotech Mikrobiomik began recruiting for its DIREBIOT Phase II clinical trial at Ramón y Cajal University Hospital (Madrid), testing a microbiota‑based, antibiotic‑free therapy (MBK‑01) for recurrent uncomplicated diverticulitis—a novel treatment path targeting microbiome modulation
• In May 2025, a study published in Annals of Internal Medicine found that inclusion of nuts and seeds in the diet does not increase diverticulitis risk, debunking longstanding dietary restrictions and potentially easing nutritional guidance for patients

SKU-67072